|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||114.73 - 119.87|
|52 Week Range||77.50 - 181.07|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.
Guardant Health revealed the results of its colon cancer detection test. But shares of rival Exact Sciences surged. Here's why.
What happened Shares of Exact Sciences (NASDAQ: EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its Oncotype DX tests will be showcased at the upcoming American Society of Clinical Oncology (ASCO) annual meeting in June.